By Peter Doshi | BMJ | May 18, 2021 After rollout under emergency authorisation, manufacturers of covid-19 vaccines now have their sights on regulatory approval. But what’s the rush, asks Peter Doshi, and is just six months of data from now unblinded trials acceptable? In April 2021, Pfizer and Moderna announced efficacy results at the six […]
Source